Industry supported session

This session will be included in the accredited BLADDR live stream.   Learn more

Back to programme

Thursday, October 5, 2017 -
11:45 to 12:45
Chair: Robert Jones
Speakers: Joaquim Bellmunt,  Robert Jones, Shahrokh F. Shariat
 
11:45-11:49 - Welcome and Opening remarks
11:49-12:01 - Role of PD-1 Pathway Inhibition in mUC - J. Bellmunt, US
12:01-12:13 - Quality of Life (QoL) considerations for mUC patients - R. Jones, UK
12:13-12:25 - Clinical aspects of immunotherapy in urothelial carcinoma - S. Shariat, Austria
12:25-12:45 - Panel Discussion / Q&A / Closing remarks
Chairmen: 

Robert Jones